Clinical Trials

Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, are not eligible for enrollment in this study. The purpose of this study is to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study will be ...

The primary purpose of this study is to determine pre-surgical and post-surgical predictors of the duration and severity of glucocorticoid withdrawal in patients undergoing a curative surgery for cortisol excess.

The purpose of this study is to find out about the safety and effectiveness of an experimental drug called SPI-62 for the treatment of Cushing’s syndrome. Experimental means that the drug is not approved by health authorities including the United States Food and Drug Administration (FDA) for the treatment of Cushing’s syndrome.

The study's primary goal is to learn more about the possible impact of SPI-62 on the type of Cushing’s syndrome subject's have. The study's secondary goal is to assess SPI-62's safety and side effects, if any. Additionally, the study will look at the possible effect of SPI-62 ...

This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.

The purpose of this study is to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

The primary purpose of this study is to further document the long-term safety and tolerability profile of osilodrostat in routine clinical practice over a 3-year follow-up period when administered as monotherapy or in combination with other therapies in patients with endogenous Cushing’s Syndrome (CS).

The purpose of this study is to evaluate the effectiveness and safety of  ATR-101 for the treatment of adults who have internally caused Cushings syndrome.

The purpose of this study is to assess the effectiveness of Relacorilant for the treatment of hypercortisolism in patients with cortisol-secreting adrenal adenomas or hyperplasia, based on glycemic and blood pressure (BP) control at Week 22 compared with placebo. and to assess the safety of relacorilant for the treatment of hypercortisolism.

The purpose of this study is to characterize adrenal steroid synthesis and metabolism in patients with nonfunctioning adrenal tumors (NF), adrenal tumors with subclinical Cushing Syndrome (SCS) and Cushing Syndrome (CS). The study also aims to characterize altered metabolites and disruptive metabolic pathways, and to connect adrenalectomy-induced changes in β-cell function and insulin sensitivity with the preoperative metabolic profile in patients who have NF, SCS and CS adrenal tumors.

The purpose of this study is to determine prevalence and incidence of osteopenia, osteoporosis, and fractures in patients with adenomas based on hormonal sub-type, and to determine the effect of abnormal steroid metabolome on bone density, bone metabolism, and fractures.

The purpose of this research is to follow people with adrenal disorders in order to make conclusions about the natural history of a particular adrenal disease as well as effect of various therapies and interventions decided on by you and your medical team. In addition, we will collect biomaterial from you at times you are being evaluated which will be used to discover novel biomarkers which can potentially improve the accuracy of current diagnostic tests and affect the management of patients with adrenal disorders. We will also include a control group (without known adrenal disease) to compare to the volunteers ...